CAR-T treatment targeting BCMA for hard-to-treat myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent to join the study
- You have relapsed or refractory multiple myeloma or another plasma cell disease, after standard treatment and/or after transplant
- Your cancer must show BCMA on cell surface (the trial checks this)
- You must be 18 to 75 years old and expected to live more than 3 months
- Your heart, liver, kidneys, and breathing tests must be strong enough for treatment (specific lab and scan cutoffs)
- You must be able to attend visits and follow study rules; you should not have conditions that would block cell-therapy safety
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This study tests a new CAR-T cell therapy that targets a protein called BCMA on myeloma cells. It is for patients with newly diagnosed multiple myeloma who cannot have a standard stem cell transplant. The therapy is a one-time infusion of your own immune cells that are modified to attack the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.